Therapix Biosciences of Tel Aviv, a specialty clinical-stage pharmaceutical company developing cannabinoid-based drugs, last week signed a memorandum of understanding with California-based CURE Pharmaceutical to enter into a research collaboration with Israel’s Assuta Medical Centers.
The two biopharma companies will jointly advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. Assuta will support the early research and development of potential projects at its eight hospitals and medical centers.
Robert Davidson, CEO of CURE Pharmaceutical, noted that Israel “is at the forefront of cannabinoid-based research in the world” and therefore is “the perfect place to start the development of these products.”
“As CURE focuses on targeting unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options, we are continuously looking to help bring new therapeutic cannabinoid-based products to market and further efforts toward the creation of personalized medicine,” Davidson said.
Therapix Biosciences’ lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourette’s syndrome. The company intends to initiate a Phase 1 clinical study of another compound, THX-ULD01, for the treatment of mild cognitive impairment, for which no FDA-approved therapies currently exist. Approvals for these indications may lead to other applications including pain, cancer, anti-inﬂammatory, dermatology, and psychiatric disorders.
Both compounds repurpose an FDA-approved synthetic THC, the principal psychoactive constituent of cannabis.
Therapix also is developing unique cannabinoid delivery technologies to improve drug administration, including nasal and sublingual delivery methods for THC, with formulations designed to increase efficacy compared with standard oral administration.